The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP. Read More

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018. Read More

Companies and academic researchers have often had a dichotomous relationship, but new models are aligning the relationship. Read More

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Centogene BV filed to sell 4 million common shares on Nasdaq for between $14 and $16 in an IPO expected to raise $60 million at the midpoint. Read More

“We’re in a global market. We need to stop being parochial and work globally from the beginning.” Read More

The FDA’s Janet Woodcock, director of the Center for Drug Evaluation and Research, testified before a House subcommittee on the national security risk raised by U.S. reliance on China exports of active pharmaceutical ingredients (API). Read More

Biotech money raised to-date and by month in 2019, including public, private and other financings. Read More

Follow-ons completed by biopharma companies in October 2019. Read More

Completed and pending initial public offerings by biopharma companies in October 2019. Read More

Private placements and other private financings of public biopharma companies in October 2019. Read More

Venture capital and other private financings of private biopharma companies in October 2019. Read More

Triggered milestone payments disclosed by biopharma companies in October 2019. Read More

The top 10 biopharma stock gainers and losers for the week of Oct. 28–Nov. 1, 2019. Read More

These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index. Read More

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes. Read More